United Capital Management of KS’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.06M | Buy |
28,038
+619
| +2% | +$133K | 0.92% | 42 |
|
|
2026
Q1 | $5.96M | Buy |
27,419
+312
| +1% | +$69.2K | 0.9% | 41 |
|
|
2025
Q4 | $6.19M | Buy |
27,107
+316
| +1% | +$72K | 0.87% | 41 |
|
|
2025
Q3 | $6.2M | Buy |
26,791
+992
| +4% | +$202K | 0.84% | 41 |
|
|
2025
Q2 | $4.79M | Buy |
25,799
+341
| +1% | +$63.4K | 0.75% | 44 |
|
|
2025
Q1 | $5.33M | Buy |
25,458
+594
| +2% | +$115K | 1.1% | 34 |
|
|
2024
Q4 | $4.42M | Buy |
24,864
+314
| +1% | +$57.7K | 0.8% | 40 |
|
|
2024
Q3 | $4.85M | Sell |
24,550
-3,962
| -14% | -$739K | 1.05% | 34 |
|
|
2024
Q2 | $4.89M | Buy |
28,512
+172
| +0.6% | +$28.5K | 1.08% | 34 |
|
|
2024
Q1 | $5.16M | Sell |
28,340
-853
| -3% | -$147K | 1.18% | 30 |
|
|
2023
Q4 | $4.52M | Buy |
29,193
+1,007
| +4% | +$147K | 1.37% | 31 |
|
|
2023
Q3 | $4.2M | Buy |
28,186
+55
| +0.2% | +$8.07K | 1.43% | 26 |
|
|
2023
Q2 | $3.79M | Buy |
28,131
+5,245
| +23% | +$769K | 1.21% | 33 |
|
|
2023
Q1 | $3.65M | Buy |
22,886
+971
| +4% | +$148K | 1.36% | 30 |
|
|
2022
Q4 | $3.54M | Buy |
21,915
+481
| +2% | +$73.8K | 1.46% | 27 |
|
|
2022
Q3 | $2.88M | Buy |
21,434
+240
| +1% | +$34.4K | 1.35% | 34 |
|
|
2022
Q2 | $3.25M | Sell |
21,194
-5,635
| -21% | -$861K | 1.53% | 30 |
|
|
2022
Q1 | $4.35M | Sell |
26,829
-398
| -1% | -$57.8K | 1.69% | 24 |
|
|
2021
Q4 | $3.69M | Buy |
27,227
+665
| +3% | +$78.6K | 1.38% | 32 |
|
|
2021
Q3 | $2.87M | Buy |
26,562
+324
| +1% | +$37K | 1.17% | 37 |
|
|
2021
Q2 | $2.96M | Buy |
26,238
+980
| +4% | +$110K | 1.21% | 36 |
|
|
2021
Q1 | $2.7M | Buy |
25,258
+1,075
| +4% | +$115K | 1.24% | 34 |
|
|
2020
Q4 | $2.59M | Buy |
24,183
+1,492
| +7% | +$143K | 1.18% | 34 |
|
|
2020
Q3 | $1.99M | Buy |
22,691
+987
| +5% | +$92.9K | 1.04% | 36 |
|
|
2020
Q2 | $2.13M | Buy |
21,704
+2,860
| +15% | +$252K | 1.24% | 35 |
|
|
2020
Q1 | $1.44M | Buy |
18,844
+1,458
| +8% | +$124K | 1.21% | 31 |
|
|
2019
Q4 | $1.54M | Buy |
17,386
+1,389
| +9% | +$115K | 0.97% | 38 |
|
|
2019
Q3 | $1.19M | Buy |
15,997
+1,143
| +8% | +$78.4K | 0.87% | 42 |
|
|
2019
Q2 | $1.09M | Buy |
14,854
+358
| +2% | +$28.1K | 0.82% | 43 |
|
|
2019
Q1 | $1.14M | Buy |
14,496
+1,287
| +10% | +$105K | 0.89% | 41 |
|
|
2018
Q4 | $1.22M | Buy |
13,209
+1,089
| +9% | +$95.8K | 1.13% | 30 |
|
|
2018
Q3 | $1.1M | Buy |
+12,120
| New | +$1.15M | 0.89% | 36 |
|
Other funds holding ABBV
United Capital Management of KS's ABBV Position: Q2 2026 in Review
United Capital Management of KS increased its AbbVie (ABBV) stake by 2.3% in Q2 2026, buying an estimated $133K and bringing the position to 28,038 shares worth $7.06M. The position accounts for 0.92% of the portfolio, ranked #42.
United Capital Management of KS first reported a position in ABBV in Q3 2018 and has held it in 32 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- United Capital Management of KS held 28,038 shares of AbbVie worth $7.06M as of Q2 2026.
- United Capital Management of KS bought 619 AbbVie shares in Q2 2026, an estimated $133K.
- AbbVie made up 0.92% of United Capital Management of KS's portfolio in Q2 2026, its #42 holding.
- United Capital Management of KS first reported a position in AbbVie in Q3 2018 and has held it in 32 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on United Capital Management of KS's 13F filing for Q2 2026, filed 5 Aug 2026.